A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression
Lantern Pharma Inc.
Lantern Pharma Inc.
Australian & New Zealand Children's Haematology/Oncology Group
Onconic Therapeutics Inc.
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Grupo Espanol de Investigacion en Sarcomas
Shenzhen Institute for Innovation and Translational Medicine
Second Affiliated Hospital of Guangzhou Medical University
Translational Oncology Research International
Elro Pharma
National Cancer Center, Korea
Xanthus Pharmaceuticals, Inc.